Trinity Biotech (TRIB) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Trinity Biotech has reported a 14% year-on-year revenue growth in Q2 2024, driven by high demand for their TrinScreen HIV product, with total revenues reaching $15.8 million. The company’s Point-of-Care product line witnessed a remarkable 119% growth compared to the previous year. Trinity Biotech remains on track to hit $20 million in annualized EBITDASO on revenues of approximately $75 million by Q2 2025, reflecting strong performance and strategic initiatives.
For further insights into TRIB stock, check out TipRanks’ Stock Analysis page.
